Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function
Sponsor: NGM Biopharmaceuticals, Inc
Listed as NCT04823702, this PHASE1 trial focuses on Impaired Hepatic Function and remains completed. Sponsored by NGM Biopharmaceuticals, Inc, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2021 — Feb 2022 [monthly]
Recruiting PHASE1
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NGM Biopharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .